| Literature DB >> 29172967 |
Donatella Panatto1,2, Daniela Amicizia1,2, Lucia Arata1, Piero Luigi Lai1,2, Roberto Gasparini1,2.
Abstract
Squalene-based adjuvants have been included in influenza vaccines since 1997. Despite several advantages of adjuvanted seasonal and pandemic influenza vaccines, laypeople's perception of such formulations may be hesitant or even negative under certain circumstances. Moreover, in Italian, the term "squalene" has the same root as such common words as "shark" (squalo), "squalid" and "squalidness" that tend to have negative connotations. This study aimed to quantitatively and qualitatively analyze a representative sample of Italian web pages mentioning squalene-based adjuvants used in influenza vaccines. Every effort was made to limit the subjectivity of judgments. Eighty-four unique web pages were assessed. A high prevalence (47.6%) of pages with negative or ambiguous attitudes toward squalene-based adjuvants was established. Compared with web pages reporting balanced information on squalene-based adjuvants, those categorized as negative/ambiguous had significantly lower odds of belonging to a professional institution [adjusted odds ratio (aOR) = 0.12, p = .004], and significantly higher odds of containing pictures (aOR = 1.91, p = .034) and being more readable (aOR = 1.34, p = .006). Some differences in wording between positive/neutral and negative/ambiguous web pages were also observed. The most common scientifically unsound claims concerned safety issues and, in particular, claims linking squalene-based adjuvants to the Gulf War Syndrome and autoimmune disorders. Italian users searching the web for information on vaccine adjuvants have a high likelihood of finding unbalanced and misleading material. Information provided by institutional websites should be not only evidence-based but also carefully targeted towards laypeople. Conversely, authors writing for non-institutional websites should avoid sensationalism and provide their readers with more balanced information.Entities:
Keywords: Influenza vaccines; influenza; internet; misinformation; squalene; squalene-based adjuvants; vaccine adjuvants
Mesh:
Substances:
Year: 2018 PMID: 29172967 PMCID: PMC5893210 DOI: 10.1080/21645515.2017.1407483
Source DB: PubMed Journal: Hum Vaccin Immunother ISSN: 2164-5515 Impact factor: 3.452
Characteristics of the web pages analyzed, by general tone.
| Variable | Level | Positive/neutral ( | Negative/ambiguous ( |
|---|---|---|---|
| Top-level domain, % (95% CI) | .it | 72.7 (57.2–85.0) | 60.0 (43.3–75.1) |
| .com | 6.8 (1.4–18.7) | 10.0 (2.8–23.7) | |
| .org | 11.4 (3.8–24.6) | 12.5 (4.2–26.8) | |
| Other | 9.1 (2.5–21.7) | 17.5 (7.3–32.8) | |
| Website source, % (95% CI) | Institutional | 43.2 (28.3–59.0) | 7.5 (1.6–20.4) |
| Non-institutional | 56.8 (41.0–71.7) | 92.5 (79.6–98.4) | |
| Web pages with at least 1 picture, % (95% CI) | — | 34.1 (20.5–50.0) | 75.0 (58.8–87.3) |
| Number of pictures, median (range) | — | 0 (0–3) | 1 (0–8) |
| GulpEASE index, mean (SD) | — | 42.9 (3.7) | 46.4 (3.6) |
| Common words, % (SD) | — | 73.6 (5.3) | 76.3 (4.7) |
Categories of images, by general tone.
| Category | Positive/neutral, | Negative/ambiguous, |
|---|---|---|
| Vaccination | 7 | 6 |
| Syringe | 2 | 10 |
| Vaccine | 3 | 6 |
| Virus | 0 | 4 |
| Sharks/monsters | 0 | 3 |
| Other | 9 | 29 |
Multivariable logistic regression to predict the general tone of web pages analyzed.
| Variable | aOR | 95% CI | |
|---|---|---|---|
| Website source (institutional vs non-institutional) | 0.12 | 0.03–0.50 | .004 |
| N of pictures (1-unit increase) | 1.91 | 1.05–3.48 | .034 |
| GulpEASE index (1-unit increase) | 1.34 | 1.09–1.65 | .006 |
| % common words (1-unit increase) | 1.01 | 0.88–1.16 | .89 |
Figure 1.Tag clouds with 50 or more common words found among positive/neutral (A) and negative/ambiguous (B) web pages.
Claims around squalene and/or squalene-based adjuvants found among negative/ambiguous web pages.
| Myth | % | 95% CI |
|---|---|---|
| Squalene is a toxic/unnatural substance | 22.5 | 10.8–38.5 |
| Efficacy of influenza vaccines with squalene-based adjuvants is not demonstrated | 5.0 | 0.6–16.9 |
| Too little/no safety data on squalene-based adjuvants are available; there are more risks than benefits regarding squalene-based adjuvants | 27.5 | 14.6–43.9 |
| Squalene and/or squalene-based adjuvants are/may be directly linked to deaths | 20.0 | 9.1–35.6 |
| Squalene and/or squalene-based adjuvants (may) cause autoimmune disorders | 47.5 | 31.5–63.9 |
| Squalene and/or squalene-based adjuvants (may) cause the so-called Gulf War Syndrome | 52.5 | 36.1–68.5 |
| Conspiracy theories around squalene and/or squalene-based adjuvants | 35.0 | 20.6–51.7 |
Myths and facts about squalene and squalene-based adjuvants in influenza vaccines.
| Myths | Facts | Ref. |
|---|---|---|
| Squalene is a toxic/unnatural substance | Squalene is a fully biocompatible and biodegradable substance, being the direct predecessor of cholesterol. About 1 g of squalene is synthetized daily in the human liver and is also introduced through the normal diet. A considerable amount of squalene can be found in human sebum and it is largely used by the cosmetic industry. | |
| Efficacy of influenza vaccines with squalene-based adjuvants is not demonstrated | Several meta-analyses have shown that influenza vaccines containing squalene-based adjuvants (such as MF59®) are both immunogenic and efficacious in preventing influenza and its complications. | |
| Too little/no safety data on squalene-based adjuvants are available; there are more risks than benefits regarding squalene-based adjuvants | Tens of clinical and observational studies as well as systematic reviews/meta-analyses have shown an acceptable safety profile of MF59®-adjuvanted influenza vaccine. Although in comparison with non-adjuvanted vaccines, there is some increase in the frequency of solicited adverse events (particularly local reactions), most of which are mild. On the other hand, the frequency of unsolicited and serious adverse events tend to be lower among recipients of MF59®-adjuvanted vaccine than among those receiving conventional influenza vaccines. Moreover, to date, MF59®-adjuvanted vaccine is licensed in about 30 countries and more than 100 million doses were administered worldwide from 1997 to date. | |
| Squalene and/or squalene-based adjuvants are/may be directly linked to deaths | This myth probably comes from the so-called “Fluad case” when during the 2014–15 season 3 deaths occurred within 48 hours from vaccination with MF59®-adjuvanted influenza vaccine. As a result two batches of the vaccine were recalled as a precautionary measure. No causal link was later established. Moreover, it has been calculated that up to 20 Italian people die every day within 48 hours of vaccination by pure chance. | |
| Squalene and/or squalene-based adjuvants (may) cause autoimmune disorders | In a large ( | |
| Squalene and/or squalene-based adjuvants (may) cause the so-called Gulf War Syndrome | In 2000, American researchers reported data on a high frequency of the presence of anti-squalene antibodies among veterans with the so-called Gulf War Syndrome. The methodology of that study was criticized and, according to the US Federal Government, vaccines administered to military personnel in that period of time did not contain squalene. Anti-squalene antibodies are very frequently detectable (at low titers) among people never immunized with vaccines containing squalene. No casual association between positivity to squalene and the development of GWS has been established. The MF59®-adjuvanted vaccine does not induce anti-squalene antibodies nor increase the quantity of pre-existing anti-squalene antibodies. |